Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration
暂无分享,去创建一个
Sooyoung Chung | Kyungjin Kim | Y. Choe | G. Son | K. Rhee | H. Choe | Jeongah Kim | Sangwon Jang | Mijung Choi
[1] Sooyoung Chung,et al. Small Molecule Modulators of the Circadian Molecular Clock With Implications for Neuropsychiatric Diseases , 2019, Front. Mol. Neurosci..
[2] M. Zordan,et al. Circadian Rhythm Abnormalities in Parkinson’s Disease from Humans to Flies and Back , 2018, International journal of molecular sciences.
[3] S. Merali,et al. Circadian rhythm dysfunction: a novel environmental risk factor for Parkinson’s disease , 2017, Molecular Psychiatry.
[4] P. Franken,et al. Altered Sleep Homeostasis in Rev-erbα Knockout Mice. , 2016, Sleep.
[5] P. Chan,et al. Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese , 2015, Scientific Reports.
[6] S. Maier,et al. Microglia inflammatory responses are controlled by an intrinsic circadian clock , 2015, Brain, Behavior, and Immunity.
[7] R. Barker,et al. 'The clocks that time us'—circadian rhythms in neurodegenerative disorders , 2014, Nature Reviews Neurology.
[8] A. Roberts,et al. Pharmacological Targeting of the Mammalian Clock Regulates Sleep Architecture and Emotional Behavior , 2014, Nature Communications.
[9] M. Lazar,et al. Nuclear receptor Rev-erbα: up, down, and all around , 2014, Trends in Endocrinology & Metabolism.
[10] Sooyoung Chung,et al. Impact of Circadian Nuclear Receptor REV-ERBα on Midbrain Dopamine Production and Mood Regulation , 2014, Cell.
[11] R. Barker,et al. Sleep and circadian rhythm regulation in early Parkinson disease. , 2014, JAMA neurology.
[12] H. Kennedy,et al. Alteration of Daily and Circadian Rhythms following Dopamine Depletion in MPTP Treated Non-Human Primates , 2014, PloS one.
[13] D. Holtzman,et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. , 2013, The Journal of clinical investigation.
[14] J. Honnorat,et al. Mapping and kinetics of microglia/neuron cell‐to‐cell contacts in the 6‐OHDA murine model of Parkinson's disease , 2013, Glia.
[15] A. Chawla,et al. Circadian Gene Bmal1 Regulates Diurnal Oscillations of Ly6Chi Inflammatory Monocytes , 2013, Science.
[16] J. Eeckhoute,et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy , 2013, Nature Medicine.
[17] B. Cho,et al. Relationship between Microglial Activation and Dopaminergic Neuronal Loss in 6-OHDA-induced Parkinsonian Animal Model , 2013 .
[18] S. Ohdo,et al. A Disruption Mechanism of the Molecular Clock in a MPTP Mouse Model of Parkinson’s Disease , 2013, NeuroMolecular Medicine.
[19] J. Takahashi,et al. Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists , 2012, Nature.
[20] A. Loudon,et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines , 2011, Proceedings of the National Academy of Sciences.
[21] C. Colwell,et al. Circadian dysfunction in a mouse model of Parkinson's disease , 2011, Experimental Neurology.
[22] Woong Sun,et al. Dissociation of Progressive Dopaminergic Neuronal Death and Behavioral Impairments by Bax Deletion in a Mouse Model of Parkinson's Diseases , 2011, PloS one.
[23] D. Kojetin,et al. Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. , 2011, ACS chemical biology.
[24] D. Finn,et al. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat , 2011, Neuroscience.
[25] D. Bechtold,et al. Circadian dysfunction in disease. , 2010, Trends in pharmacological sciences.
[26] M. Goldberg,et al. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention , 2010, Neurobiology of Disease.
[27] Erik D. Herzog,et al. A circadian clock in macrophages controls inflammatory immune responses , 2009, Proceedings of the National Academy of Sciences.
[28] D. Dexter,et al. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6‐hydroxydopamine model of Parkinson’s disease , 2009, Journal of neurochemistry.
[29] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[30] A. Hartmann,et al. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice , 2008, Experimental Neurology.
[31] S. Dunnett,et al. Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model , 2006, Journal of Neuroscience Methods.
[32] C. Ferrari,et al. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra , 2006, Neurobiology of Disease.
[33] C. Tanner,et al. Excessive daytime sleepiness and subsequent development of Parkinson disease , 2005, Neurology.
[34] Nicolas Cermakian,et al. Differential Control of Bmal1 Circadian Transcription by REV-ERB and ROR Nuclear Receptors , 2005, Journal of biological rhythms.
[35] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[36] Ueli Schibler,et al. The Orphan Nuclear Receptor REV-ERBα Controls Circadian Transcription within the Positive Limb of the Mammalian Circadian Oscillator , 2002, Cell.
[37] Peter Riederer,et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.
[38] P. Riederer,et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.
[39] W. H. Oertel,et al. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.
[40] Minoru Harada,et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.
[41] P. Mcgeer,et al. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions , 1989, Brain Research.
[42] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[43] C. Comella. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. , 2006, Journal of neural transmission. Supplementum.
[44] A. Schapira,et al. Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.